Oral antibiotics decrease urinary isoflavonoid excretion in children after soy consumption

Brunhild M Halm1, Adrian A Franke, Leslie A Ashburn

  • 1Cancer Research Center of Hawai'i, Cancer Prevention & Control Program and Kapi'olani Medical Center for Women and Children, Honolulu, HI 96813, USA.

Nutrition and Cancer
|April 30, 2008
PubMed

Insights

Oral antibiotics (OABX) significantly reduce urinary isoflavone excretion rates (UIERs) in soy-consuming children. This suggests OABX alter gut bacteria, impacting how the body processes beneficial soy compounds.

Area of Science:

  • Human Nutrition and Metabolism
  • Microbiology and Gut Health
  • Pharmacology

Background:

  • Isoflavones (IFLs) are plant compounds found in soy with potential health benefits.
  • The gut microbiome plays a crucial role in metabolizing IFLs.
  • The impact of oral antibiotics (OABX) on IFL metabolism in children is not well understood.

Purpose of the Study:

  • To investigate how OABX affect urinary isoflavone excretion rates (UIERs) in children who consume soy.
  • To explore the potential role of gut microflora alterations in mediating these effects.

Main Methods:

  • A cohort of 11 children (ages 4-17) provided paired urine samples: one during OABX treatment and one when healthy.
  • Participants consumed a standardized dose of soy nuts.
  • Urinary IFLs (nonmetabolites and metabolites) were quantified using liquid chromatography-mass spectrometry.

Main Results:

  • Urinary excretion rates for genistein (GE), other nonmetabolite IFLs, and total IFLs were significantly lower during OABX treatment compared to when healthy (P < 0.05).
  • A trend towards increased O-desmethylangolensin (DMA) production was observed during OABX use (P = 0.13).
  • Reduced IFLs in urine may be linked to OABX-induced changes in gut bacteria or infection-related processes.

Conclusions:

  • Oral antibiotic use significantly decreases the urinary excretion of isoflavones in soy-consuming children.
  • This reduction highlights the influence of the gut microbiome on IFL bioavailability and metabolism.
  • Further research is needed to fully elucidate the mechanisms behind OABX-mediated changes in IFL processing.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Urinary Tract Calculi IV: Nutrition Therapy and Prevention01:27

Urinary Tract Calculi IV: Nutrition Therapy and Prevention

Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...